Oral pazopanib improves sight in macular degeneration cases

Oral pazopanib improves sight in macular degeneration cases
Oral pazopanib is well tolerated and improves mean best-corrected visual acuity, central retinal lesion thickness, and central retinal thickness at day 29 in a small, per-protocol, non-rescued population of patients with age-related macular degeneration, according to a study published online Oct. 10 in JAMA Ophthalmology.

(HealthDay)—Oral pazopanib is well tolerated and improves mean best-corrected visual acuity, central retinal lesion thickness, and central retinal thickness at day 29 in a small, per-protocol, non-rescued population of patients with age-related macular degeneration (AMD), according to a study published online Oct. 10 in JAMA Ophthalmology.

Megan M. McLaughlin, from GlaxoSmithKline in King of Prussia, Pa., and colleagues conducted a 14-day, placebo-controlled, dose-rising study in 72 healthy participants (oral pazopanib tablets, 5 to 30 mg daily) and a 28-day phase 2a open-label study in 15 patients with subfoveal choroidal neovascularization secondary to AMD (15 mg daily).

The researchers found that oral pazopanib was well tolerated by all. Rescue therapy before day 29 was received by six of the 15 patients, all of whom had the CFH Y402H CC "high-risk" genotype for AMD. The other nine patients completed the study without rescue with improvements from baseline in best-corrected visual acuity, central retinal lesion thickness, and central retinal thickness. The association between the CFH Y402H T allele ("low risk" for AMD) trended toward improvement.

"It is postulated that CFH Y402H genotype may help predict which respond to pazopanib," the authors write.

Several authors disclosed financial ties to GlaxoSmithKline, which manufactures pazopanib and funded the study.

More information: Abstract
Full Text

add to favorites email to friend print save as pdf

Related Stories

Genotyping IDs long-term risk of macular degeneration

Nov 13, 2012

(HealthDay)—Genotyping of two genetic risk alleles can be used to estimate the long-term risk of early and late age-related macular degeneration (AMD), but knowing the phenotype is important in assessing ...

GEN reports on ocular therapeutics targeting the retina

Sep 10, 2012

Therapies for retinal diseases are expected to overtake those for glaucoma by 2014, reports Genetic Engineering & Biotechnology News (GEN). Because current retinal disease treatments only improve vision for si ...

Supplement aids age-related macular degeneration

Mar 26, 2013

(HealthDay)—A supplement containing a combination of lutein, zeaxanthin, and ω-3 long-chain polyunsaturated fatty acids (LC-PUFAs) significantly benefits patients with age-related macular degeneration ...

Recommended for you

Team creates device to alleviate dry eye

8 hours ago

A search for medical needs in eye clinics led Stanford Biodesign fellows to develop an implantable neurostimulator that painlessly increases natural tear production.

Scientists discover gene tied to profound vision loss

Jan 16, 2015

An exhaustive hereditary analysis of a large Louisiana family with vision issues has uncovered a new gene tied to an incurable eye disorder called retinitis pigmentosa, according to an examination led by ...

Eye surgeon uses stem cells to repair damaged corneas

Jan 14, 2015

In Hyderabad, India, Sayan Basu is using stem cells in a pilot project to restore the eyesight of patients with damaged corneas. If proven successful, the procedure could mean that Indian citizens can avoid ...

What you need to know about pediatric glaucoma

Jan 13, 2015

One evening, five years ago, Brittni Powell did what a lot of young mothers do and gazed into her 2-month-old son's eyes. What she saw had Brittni and her husband Byron heading immediately to a Montgomery-area hospital emergency ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.